NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle size, polydispersity index (PdI), zeta potential, entrapment efficiency (EE), stability, release studies and cytotoxicity studies (MTT assay). The optimized NANOGEF exhibited particle size of 74.06 ± 9.73 d.nm, PdI of 0.339 ± 0.029 and EE of 99.76 ± 0.015%. The TEM study revealed spherical shape of NANOGEF formulations. The slow and sustained release behavior was exhibited by all NANOGEFs. The effects of surfactants were observed not only on particle size but also on zeta potential, entrapment efficiency, stability and release studies. The MTT assay revealed 4.5 times incre...
This study was aimed to evaluate the impact of surfactants used for nanostructured lipid carriers (N...
The incorporation of zerumbone (Zer) into nanostructured lipid carrier (NLC) is hypothesized to incr...
Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and am...
Gefitinib (GEF) is the first epidermal growth factor receptor (EGFR)-targeting agent launched as an ...
Gefitinib (GFT) is a tyrosine kinase inhibitor drug used as a first-line treatment for patients with...
Navya Sree Kola Srinivas,1 Ruchi Verma,2 Girish Pai Kulyadi,1 Lalit Kumar1 1Department of Pharmaceu...
The current study focuses on the development and evaluation of nano lipidic carriers (NLCs) for code...
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib w...
Background: Colorectal cancer is one of the most challenging cancers to treat. Exploring novel thera...
Anticancer agents that target both tumor cells and angiogenesis are of potential interest for gliobl...
Glioblastoma (GBM) is the most common malignant neoplasm in adults among all CNS gliomas, with the 5...
International audienceIncreasing intracellular drug concentration using nanocarriers can be a potent...
Glioblastoma Multiforme is a deadly cancer of glial cells with very low survival rates. Current trea...
This work aimed to optimize a celecoxib (CXB)-loaded solid lipid nanoparticles (SLN) colon delivery ...
The aim of this thesis was to develop nanocarriers for efficient delivery of two low molecular weigh...
This study was aimed to evaluate the impact of surfactants used for nanostructured lipid carriers (N...
The incorporation of zerumbone (Zer) into nanostructured lipid carrier (NLC) is hypothesized to incr...
Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and am...
Gefitinib (GEF) is the first epidermal growth factor receptor (EGFR)-targeting agent launched as an ...
Gefitinib (GFT) is a tyrosine kinase inhibitor drug used as a first-line treatment for patients with...
Navya Sree Kola Srinivas,1 Ruchi Verma,2 Girish Pai Kulyadi,1 Lalit Kumar1 1Department of Pharmaceu...
The current study focuses on the development and evaluation of nano lipidic carriers (NLCs) for code...
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib w...
Background: Colorectal cancer is one of the most challenging cancers to treat. Exploring novel thera...
Anticancer agents that target both tumor cells and angiogenesis are of potential interest for gliobl...
Glioblastoma (GBM) is the most common malignant neoplasm in adults among all CNS gliomas, with the 5...
International audienceIncreasing intracellular drug concentration using nanocarriers can be a potent...
Glioblastoma Multiforme is a deadly cancer of glial cells with very low survival rates. Current trea...
This work aimed to optimize a celecoxib (CXB)-loaded solid lipid nanoparticles (SLN) colon delivery ...
The aim of this thesis was to develop nanocarriers for efficient delivery of two low molecular weigh...
This study was aimed to evaluate the impact of surfactants used for nanostructured lipid carriers (N...
The incorporation of zerumbone (Zer) into nanostructured lipid carrier (NLC) is hypothesized to incr...
Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and am...